Pimavanserin — Parkinson’s Disease Psychosis
NDx participated in the clinical development of pimavanserin, which became the first FDA-approved medication specifically indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
The FDA approved Nuplazid in 2016, providing an important new treatment option for individuals experiencing these challenging symptoms of Parkinson’s disease.



